Cerebral autoregulation is preserved in multiple system atrophy: A transcranial Doppler study.

Patients with multiple system atrophy (MSA) present large changes in blood pressure (BP) due to autonomic disturbances. We analyzed how this change may influence dynamic cerebral autoregulation (DCA). Simultaneous recordings of arterial BP (Finapres) and middle cerebral artery (MCA) blood flow velocity (BFV) (transcranial Doppler) were performed in 10 patients with MSA (61 +/- 12 yr of age) and 12 healthy volunteers (61 +/- 11 yr of age): cerebral BFV response to oscillations in mean BP was studied in the supine position by cross-spectral analysis of mean BP and mean MCA BFV. The DCA was also studied during the decrease in BP the first seconds when standing up from a sitting position by the assessment of the cerebrovascular resistance index (CR; mean BP/mean MCA BFV ratio). The MCA BFV/BP cross-spectral analysis showed a phase for the mid-frequency band (0.07-0.2 Hz) significantly larger in MSA, suggesting more active autoregulation in response to larger changes in BP. Changes in CR reflecting the rate of autoregulation, when standing did not differ between the two groups. These data suggest that dynamic cerebral autoregulation is preserved in MSA.     

脂蛋白脂酶Hind Ⅲ基因多态性与动脉硬化性脑梗死的关系

目的研究脂蛋白脂酶HindⅢ基因多态性与动脉硬化性脑梗死发病的关系及其对血脂、颈动脉斑块的影响。方法选择166例动脉硬化性脑梗死患者，采用聚合酶链反应-限制性片段长度多态性分析检测脂蛋白脂酶的HindⅢ基因多态性，颈动脉超声多普勒检查颈总动脉内膜中层厚度和颈动脉斑块，并与72名健康对照比较。结果在脑梗死组中H＋H＋基因型频率和H＋等位基因频率明显高于对照组（OR=2．267，P=0．004；OR=1．903，P=0．004），而血脂水平、颈总动脉内膜中层厚度、颈动脉斑块分级与对照组比较差异无统计学意义。结论脂蛋白脂酶的HindⅢ基因多态性与脑梗死的关系密切，H＋H＋基因型可能是脑梗死的危险因素。     

28例颈内动脉系统急性脑梗塞动脉溶栓治疗

目的分析颈内动脉系统急性脑梗塞动脉溶栓治疗的有效性和安全性。方法对28例颈内动脉急性脑梗塞的患者进行了动脉溶栓治疗．通过造影显示血管再通情况。术后即刻和24h后分别行头颅CT扫描以了解有无颅内出血（ICH）。术后第90天采用Barthel指数（BI）对患者生活状态进行评估。结果28例患者经动脉溶栓治疗，堵塞血管再通18例，部分再通6例，未通4例；症状性颅内出血8例，死亡5例。术后第90天，生活状态优者14例，良者8例，差或者死亡6例。再通患者生活状态明显优于部分再通及未通患者。结论动脉溶栓具有较高的症状性颅内出血率及死亡率。再通患者生活状态较好。     

创伤性迟发性颅内血肿的诊断和治疗

目的 探讨创伤性、迟发性颅内血肿的早期诊断和治疗的临床效果。方法 对22例病人的发病年龄、性别、伤因、早期诊断和治疗效果进行了回顾性分析。经过2—6个月，按GOS评定治疗效果。结果 良好者12例，中残者5例，重残者1例，植物生存者1例，死亡者3例，死亡率为14％。结论 早期诊断和治疗本病对于提高治愈率和降低死亡率至关重要，早期手术治疗本病，乃是多数病人首选的治疗方法。     

急性脑梗死超早期重组组织型纤溶酶原激活物溶栓治疗的临床研究

目的:探讨发病6h内急性脑梗死给予重组组织型纤溶酶原激活物(rt-PA)溶栓治疗的疗效及并发症,并分析预后相关因素。方法:共收集本院2001-2005年70例溶栓治疗的急性脑梗死病例,其中52例静脉溶栓,18例动脉溶栓,分析比较两组病例溶栓前后及3个月随访的ESS评分及Barthel指数结果;同时分析与预后相关的因素。结果:静脉和动脉溶栓组溶栓前及溶栓30min后ESS评分及Barthel指数迅速增加,溶栓前后分值有显著差异。1个月内颅内出血率为5.77%(静脉组)和16.67%(动脉组)。3个月时ESS评分及Barthel指数较溶栓后30min的评分有显著改善。结论:6h内动脉、静脉溶栓治疗均安全有效。     

中青年脑梗死68例临床分析

脑梗死多见于老年人，但近年来中青年（16-45岁）患者逐渐增多且有年轻化趋势，深人探讨中青年脑梗死的致病因素及临床表现对其防治有重要意义。本文回顾性分析了我院自1998年1月到2004年12月问收治的中青年脑梗死患者68例，现报告如下。     

补阳还五汤对脑缺血再灌注损伤大鼠脑组织ET-1基因表达的影响

目的 :观察补阳还五汤对脑缺血再灌注损伤大鼠脑组织 ET- 1基因表达的影响 ,探讨其对脑缺血再灌注损伤的保护作用。方法 :采用线栓法制成大鼠 MCAO再灌注模型 ,并用地高辛精标记 ET- 1基因进行原位杂交。结果 :补阳还五汤治疗组缺血再灌注侧皮层及尾状核 ET- 1基因表达显著低于生理盐水对照组 (P<0 .0 5 ) ,两组大鼠缺血再灌注侧皮层和尾状核 ET- 1基因表达均显著高于健侧相应脑区 (P<0 .0 5 ,P<0 .0 1)。结论 :脑缺血再灌注可以诱导脑组织 ET- 1基因的异常表达 ,从而进一步加重脑损伤 ,补阳还五汤可在一定程度上下调脑缺血诱导的ET- 1基因的表达 ,可能是其防治缺血性脑血管病的主要作用机制之一。     

Responses of CDKs and p53 in Delayed Ischemic Neuronal Death

Stroke is a debilitating disease that affects millions each year.While in many cases cerebral ischemic in jury can be limited by effectivw resuscitation or thrombolytic treatment,the injured neurons wither in a process known as delayed neuronal death(DND).Mounting evidence indicates that DND is not simply necrosis played out in slow motion but apoptosis is triggered.Of particular interest are two groups of signal proteins that participate in apoptosis-cyclin dependent kinases(CDKs) and p53-among a myriad of signaling events after an ischemic insult.Recent investigations have shown that CDKs,a family of enzymes initially known for their role in cell cycle regulation,are activated in injured neurons in DND.As for p53,new reports suggest that its up-regulation may represent a failed attempt to rescue in jured neurons,although its up-regulation was previously considered an indication of apoptosis.These observations thus rekindle an old quest to identify new neuroprotective targets to minimize the stroke damage.In this review,the author will examine the evidence that indicates the participation of CDKs and p53 in DND and then introduce pre-clinical data to explore CDK inhibition as a potential neuroprotective target.Finally,using CDK inhibition as an example,this paper will discuss the pertinent criteria for a viable neuroprotective strategy for ischemic in jury.